Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson and partner Legend Biotech are expecting an FDA decision for their first CAR-T product, cilta-cel, in November. To prepare for the upcoming launch of the personalized cell therapy, the Big Pharma company is planning a specialized patient support program.
Takeda halted two trials for a narcolepsy candidate to examine a safety signal. The Japanese pharma also signed a gene therapy pact potentially worth over $1 billion with Selecta Biosciences. Moderna has identified "human error" as the source of contaminations in its halted COVID-19 vaccine doses in Japan. And more.
The FDA approval, which is the fourth indication for brexucabtagene autoleucel, is based on results from a multicenter, single-arm study of 71 patients, with 54 efficacy-evaluable patients.
My wife and I are in a stage of parenting where we can’t get away with spelling words aloud around the kids anymore. Our son is a great reader and
Trump Admin Subpoenaed Apple For Lawmakers' Data, More Questions Than Answers In FL Murder/Suicide and Biden Confirms U.S. Plans To Buy 500B Vaccines For Global Distribution